Deutsche Bank AG purchased a new stake in Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report) in the 2nd quarter, HoldingsChannel reports. The fund purchased 645,087 shares of the company’s stock, valued at approximately $2,251,000.
A number of other hedge funds and other institutional investors also recently modified their holdings of SANA. Alphabet Inc. acquired a new position in Sana Biotechnology during the 2nd quarter worth approximately $9,816,000. Bank of America Corp DE raised its stake in shares of Sana Biotechnology by 148.4% during the first quarter. Bank of America Corp DE now owns 2,946,861 shares of the company’s stock valued at $8,487,000 after purchasing an additional 1,760,610 shares during the period. Balyasny Asset Management L.P. acquired a new position in shares of Sana Biotechnology during the fourth quarter worth $6,834,000. Vanguard Group Inc. lifted its position in shares of Sana Biotechnology by 19.9% during the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after purchasing an additional 1,517,474 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Sana Biotechnology by 180.8% in the third quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after purchasing an additional 1,375,029 shares during the period. Institutional investors and hedge funds own 88.23% of the company’s stock.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on the stock. Weiss Ratings raised shares of Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. Wall Street Zen cut shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. TD Cowen upgraded Sana Biotechnology to a “strong-buy” rating in a research note on Monday. Bank of America dropped their target price on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Finally, Rodman & Renshaw initiated coverage on Sana Biotechnology in a research note on Monday, May 11th. They issued a “buy” rating and a $16.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.33.
Sana Biotechnology Stock Performance
Shares of Sana Biotechnology stock opened at $4.09 on Friday. The firm has a market cap of $1.22 billion, a PE ratio of -5.38 and a beta of 2.16. The firm’s 50-day simple moving average is $3.56 and its 200-day simple moving average is $3.41. Sana Biotechnology, Inc. has a 1 year low of $2.61 and a 1 year high of $6.55.
Sana Biotechnology (NASDAQ:SANA – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. On average, equities analysts predict that Sana Biotechnology, Inc. will post -0.72 earnings per share for the current year.
Sana Biotechnology Profile
Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.
The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.
Featured Stories
- Five stocks we like better than Sana Biotechnology
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report).
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
